| Revenue | SEK 21K | -69% |
| EBITDA | SEK 4K | +114% |
| Net profit | SEK 3K | -99% |
| Total assets | SEK 569K | -25% |
| Equity | SEK 560K | -26% |
| Employees | 0 | — |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 84 | 44 | 0 | 0 | 0 | 22 | 67 | 21 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | −42 | −12 | −48 | −4 | −17 | −21 | −15 | −4 | −25 | 4 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | — | — |
| EBIT | −42 | −12 | −48 | −4 | −17 | −21 | −15 | −4 | −25 | 4 |
| Net financials | −2 | 12 | −1 | −1 | −1 | −15 | 31 | −2 | 398 | 1 |
| Profit before tax | −44 | 0 | −49 | −5 | −18 | −36 | 17 | 170 | 470 | 4 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | — | −1 |
| Net profit | −44 | 0 | −49 | −5 | −18 | −36 | 17 | 170 | 470 | 3 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 323 | 219 | 170 | 156 | 158 | 121 | 190 | 289 | 760 | 569 |
| Equity | 309 | 209 | 160 | 155 | 137 | 101 | 118 | 288 | 757 | 560 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — |
| Short-term debt | 14 | 10 | 10 | 1 | 21 | 20 | 72 | 2 | 3 | 8 |
| Total debt | 14 | 10 | 10 | 1 | 21 | 20 | 72 | 2 | 3 | 8 |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
BA Audit | Audit | 2024 | — | — |
SJ | Audit | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2022 | — | — | |
| Deputy Board Member | 2022 | — | — |
No shareholder data available.
| Person | Role here | Other companies |
|---|---|---|
| Bengt Anders Larsson | Audit | 0 companies |
| Sten Johan Pharmanson | Audit | 0 companies |
| Petra Marie Liljefors | Board of Directors | 0 companies |
| Ann-Kristin Rydén | Deputy Board Member | 0 companies |